Clinical trials: Non-small Cell Lung Cancer(NSCLC)
Non-small Cell Lung Cancer, RET Fusion
A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC
This study is a single-arm, multicenter real-world clinical study designed to evaluate the safety and efficacy of Leucogen (a leukocyte-increasing agent) as a prophylactic treatment in patients with RET fusion-positive non-small…
- Conditions
- Non-small Cell Lung Cancer, RET Fusion, Pralsetinib
- Trial name
- NCT07418879
- Testing
- Pralsetinib, Leucogen
- Volunteers
- 25 people
- Sponsor
- Fudan University
Non-Small Cell Lung Cancer, Neoplasm Metastasis
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Rationale: Overexpression of epidermal growth factor receptor (EGFR) has been observed in kidney, prostate, colon, lung, breast, and other cancers, and is often associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Neoplasm Metastasis, Lung Cancer
- Trial name
- NCT00034346
- Testing
- ABX-EGF, paclitaxel, carboplatin
- Volunteers
- 194 people
- Sponsor
- Amgen
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
- Conditions
- Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma
- Trial name
- RAD301 (NCT05799274)
- Testing
- RAD301 ([68Ga]-RAD301)
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Radiopharm Theranostics, Ltd
Non Small Cell Lung Cancer
Exercise Study in Patients With Lung Cancer
In the course of their disease patients with Non small cell lung cancer (NSCLC) often experience impaired psychological and physical functioning resulting in a reduced quality of life (QoL).
- Trial name
- POSITIVE (NCT01581346)
- Testing
- Exercise intervention
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- German Cancer Research Center
Non Small Cell Lung Cancer
LUCID - LUng Cancer CIrculating Tumour Dna Study
This is a prospective observational pilot study to investigate levels of circulating tumour DNA (ctDNA) in plasma from patients with stage I to IIIB non-small cell lung cancer (NSCLC) who will undergo treatment with curative…
- Trial name
- LUCID (NCT04153526)
- Testing
- Blood sampling, Surplus Tumour Tissue sample collection from surgery, Collection or archival tumour tissue (If available)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- CCTU- Cancer Theme
Melanoma, Non Small Cell Lung Cancer
Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment
Lung Cancer and melanoma relapsed frequently whereas its very sensitive to treatment such as chemotherapy or radiotherapy. The purpose of this study is to have a better understanding of why those patients are relapsing using next…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- MSN (NCT02105168)
- Testing
- Blood sample, Tumorous biopsy, Healthy material sample
- Where
- France
- Volunteers
- 2,200 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Caregiver, Psychological Impact of Cancer and Its Treatment
Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family Caregivers
This clinical trial studies a palliative care intervention in improving symptom control and quality of life in patients with stage II-IV non-small cell lung cancer and their family caregivers.
- Conditions
- Caregiver, Psychological Impact of Cancer and Its Treatment, Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer
- Trial name
- NCT02243748
- Testing
- Palliative Therapy, quality-of-life assessment, questionnaire administration
- Where
- 5 sites in United States
- Volunteers
- 361 people
- Sponsor
- City of Hope Medical Center
Lung Cancer
Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
This is a Phase 1b pre-operative lung cancer trial wherein patients with operable lung cancer will be treated with RAD001 to evaluate the target effects of this compounds on relevant molecular pathways and on the…
- Trial name
- NCT00401778
- Testing
- RAD001
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Emory University
Lung Cancer
Effect on Patient Reported Outcomes of VATS and SABR (LILAC)
This study will monitor the effect on patients reported outcomes (PROMs) of VATS resection and SABR for NSCLC delivered at the Leeds Cancer Centre The investigator will support with this information the Shared Decision Making…
- Trial name
- LILAC (NCT02882750)
- Testing
- EORTC QLQ-C30 (version 3.0)., PS Q18, Decision Self-Efficacy Scale
- Volunteers
- 244 people
- Sponsor
- University of Leeds
Malignant Mesothelioma, Non-Small Cell Lung Carcinoma
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
This phase I trial studies the side effects and how well light dosimetry system works during photodynamic therapy with porfimer sodium in treating participants with malignant mesothelioma , non-small cell lung cancer or any other…
- Conditions
- Malignant Mesothelioma, Non-Small Cell Lung Carcinoma, Pleural Disorder
- Trial name
- NCT03678350
- Testing
- Light Dosimetry for Intranoperative Therapy, Photodynamic Therapy, Porfimer Sodium
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Non-small Cell Lung Carcinoma
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
The purpose of this study is to determine the safety, tolerability, and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with unresectable or metastatic non-small cell lung…
- Trial name
- NCT02039674
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Volunteers
- 267 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00033410
- Testing
- carboplatin, paclitaxel, tirapazamine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- California Cancer Consortium
Lung Cancer
SABR for T1-2a N1 NSCLC
Conventionally fractionated radiation therapy given over 6-7 weeks alone, sequentially, or concurrent with chemotherapy have produced poor outcomes in Stage II NSCLC in most series.
- Trial name
- NCT03321760
- Testing
- Stereotactic Ablative Radiation Therapy (SABR)
- Where
- 3 sites in United States
- Sponsor
- Indiana University
Adaptive Radiotherapy, Stereotactic Body Radiotherapy
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
This study aims to explore the safety and efficacy of eliminating the PTV (planning target volume) margins based on online adaptive stereotactic radiotherapy for patients with early-stage non-small cell lung cancer (NSCLC) or…
- Conditions
- Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer, Lung Oligometastases
- Trial name
- NCT06542159
- Testing
- Online adaptive SBRT, Conventional SBRT
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Sun Yat-sen University
Non-Small-Cell Lung Carcinoma
Molecular Imaging With Erlotinib and Bevacizumab
The patients will be treated with erlotinib and bevacizumab for a six-week period. Imaging procedures will be performed at baseline, after one week of therapy and after the six weeks of treatment.
- Trial name
- MIMEB (NCT01047059)
- Testing
- Erlotinib, Bevacizumab, Fluoro-D-glucose, Fluoro-L-thymidine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University of Cologne
Metastatic Non-small Cell Lung Cancer, Neoplasm
Body Composition and Inflammatory-Metabolic Indices in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer: The SARC-CTI Study
This retrospective, single-center observational cohort study evaluates inflammatory-metabolic, cachexia-related, and computed tomography (CT)-derived body-composition markers in patients with metastatic non-small cell lung cancer…
- Trial name
- SARC-CTI (NCT07192926)
- Testing
- Immune Checkpoint Inhibitor-Based Therapy
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 155 people
- Sponsor
- Ankara Etlik City Hospital
Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
This prospective study aims to investigate whether the time of day when immune checkpoint inhibitors (ICIs) are administered affects the efficacy of neoadjuvant immunotherapy in patients with resectable stage II-III non-small…
- Trial name
- LungTime-C02 (NCT07251582)
- Testing
- Time of Day-based Assignment for Infusion of Immune Checkpoint Inhibitor (e.g., toripalimab, or pembrolizumab) + platinum-based chemotherapy
- Where
- 2 sites in China
- Volunteers
- 186 people
- Sponsor
- Hunan Province Tumor Hospital
Lung Cancer, Non-Small Cell
A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
This is an open-label, two-arm, Phase I, dose escalation study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) of pazopanib in combination with erlotinib (Arm A) or pazopanib in…
- Trial name
- NCT00619424
- Testing
- pazopanib, erlotinib, pemetrexed
- Where
- 4 sites in United States, Italy
- Volunteers
- 58 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer
Lung cancer has the highest incidence rate in China and is also a very common cancer in the world. BPI-7711 is a new drug developed for patients with non-small cell lung cancer.
- Trial name
- NCT03386955
- Testing
- BPI-7711 Capsule
- Where
- 4 sites in China
- Volunteers
- 215 people
- Sponsor
- Beta Pharma Shanghai
Malignant Melanoma, Metastatic, Non Small Cell Lung Cancer Metastatic
Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)
The primary objective is to assess tolerability and safety of a personalized neo-antigen vaccine containing up to 15 peptides derived from somatic mutation of the individual patient's cancer, with CAF09b as adjuvant.
- Conditions
- Malignant Melanoma, Metastatic, Non Small Cell Lung Cancer Metastatic, Bladder Urothelial Carcinoma, Metastatic
- Trial name
- NeoPepVac (NCT03715985)
- Testing
- EVAX-01-CAF09b
- Where
- 2 sites in Denmark
- Volunteers
- 12 people
- Sponsor
- Herlev Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.